期刊文献+

挤出滚圆法制备阿托伐他汀钙速释微丸

Preparation of Atorvastatin Calcium Fast-release Pellets by extrusion-spheronization
下载PDF
导出
摘要 目的采用挤出滚圆法制备阿托伐他汀钙速释微丸,研究处方及制备工艺。方法在单因素实验的基础上,以微丸的粉体学性质、收率和体外溶出度为评价指标,对影响微丸成型的关键工艺参数进行正交设计优化。结果用挤出滚圆法制备的阿托伐他汀钙速释微丸圆整度好、粒度分布窄、收率高,且在30 min体外溶出均在95%以上。结论成功地制备了阿托伐他汀钙微丸,该制备工艺重现性好、质量高,具有理想的速释效果。 Objective To prepare Atorvastatin Calcium Fast-release Pellets by extrusion-spheronization and study the influence of formulation and process parameters on the properties of the pellets. Methods Using single factor test,for-mulation and preparation technology of the pellets were optimized. Effects of the key parameters on the properties of the pel-lets,yield and dissolution were investigated using orthogonal design. Results Atorvastatin Calcium Fast-release Pellets presented perfect sphericity and high yield with sharp size distribution. More than 95% of the drugs were released from the pellets in 30 min. Conclusion Atorvastatin Calcium Fast-release Pellets were successfully prepared by extrusion-spher-onization with good reproducibility and high-quality,and had a remarkable fast-release property in vitro.
作者 刘家胜 郭玉
出处 《药学研究》 CAS 2014年第12期705-706,723,共3页 Journal of Pharmaceutical Research
关键词 挤出滚圆法 阿托伐他汀钙 速释微丸 正交设计 Extrusion-spheronization Atorvastatin calcium Fast-release pellets Orthogonal design
  • 相关文献

参考文献5

二级参考文献31

  • 1[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 2[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 3[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 4[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 5[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 6[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 7[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.
  • 8[8]Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study[J]. Clin Ther 1996; 18: 853-63.
  • 9[9]Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants[J]. Circulation 1996; 94(8 Suppl): 583.
  • 10[10]Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia[J]. Atherosclerosis 1995; 115 Suppl: S20.

共引文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部